Zydus Lifesciences Limited has officially launched its Semaglutide injection in India, introducing an innovative healthcare solution for diabetes and obesity treatment. The company has received approval from the Drug Controller General of India (DCGI) for manufacturing and marketing the injection for both Type 2 Diabetes Mellitus and obesity indications.

Product Launch Details

The Semaglutide injection will be marketed under three distinct brand names to cater to different market segments:

Innovative Pen Device Technology

The launch introduces a breakthrough reusable multi-dose pen device that distinguishes Zydus' offering from existing treatment options. Unlike current alternatives that require patients to purchase multiple single-dose pens as they adjust their dosage, this innovative solution enables both clinicians and patients to conveniently select and administer different dose strengths from a single pen device.

The novel pen device offers several advantages:

• Enhanced patient convenience through single-device multiple dosing
• Improved treatment adherence due to user-friendly design
• Significant reduction in overall therapy costs
• Exclusive rights held by Zydus for the reusable pen technology
• Prefilled cartridge system for easy administration

Market Context and Health Impact

The launch addresses critical health challenges facing India, where diabetes and obesity represent serious public health concerns. According to the International Diabetes Federation, 8.9 crore adults in India are living with diabetes, representing 10.5 per cent of the country's adult population.

Obesity trends show alarming increases across demographics:

These statistics highlight the growing health crisis that GLP-1 based treatments like Semaglutide can help address. The treatment's dual indication for both diabetes and obesity positions it as a comprehensive solution for India's interconnected metabolic health challenges.

Manufacturing and Availability

Zydus will manufacture the Semaglutide injection at its Zydus Biotech Park facility in Ahmedabad. The 15mg/3ml cartridge format ensures consistent dosing while the reusable pen device provides long-term value for patients. The approximately Rs. 2,200 monthly treatment cost makes the therapy accessible compared to existing alternatives in the Indian market.

The launch follows patent expiry in India, enabling Zydus to introduce this important therapeutic option with its proprietary delivery system innovation.

Zydus Lifesciences Limited has announced the launch of Aerolife Mini™, a groundbreaking respiratory care device that represents India's first portable and foldable spacer for asthma and COPD patients. The innovation-led life-sciences company introduced this next-generation pMDI (pressurised Metered-Dose Inhaler) enhancer aimed at enhancing drug delivery and patient adherence, under an exclusive licensing arrangement with AeroDel Technology Innovations Pvt. Ltd.

Revolutionary Design Addresses Critical Healthcare Challenge

India faces a significant burden of chronic respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis, driven by rising air pollution, smoking, recurrent infections, and delayed diagnosis. Millions of patients depend on long-term inhaled therapy to control symptoms and maintain quality of life.

Enhanced Drug Delivery and Patient Adherence Features

Aerolife Mini™ addresses the limitations of conventional spacer devices, which are typically characterized by bulky form factors that limit daily portability. Traditional spacers require repeated assembly, increasing the risk of incorrect use and low real-world adherence, particularly outside the home.

The new device introduces several breakthrough features specifically designed to enhance drug delivery and patient adherence:

Strategic Partnership and Technology Innovation

This initiative aligns with Zydus' long-term strategy of building innovation-led, sustainable, and differentiated respiratory franchises through patient-centric drug devices. The launch marks a significant step in the company's approach to drive drug device led innovation in respiratory care.

About the Companies

Zydus Lifesciences Ltd. operates with the overarching purpose of empowering people with freedom to live healthier and more fulfilled lives. The global lifesciences company discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 29,000 people worldwide, including 1,500 scientists engaged in R&D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions.

AeroDel Technology Innovations Pvt. Ltd. develops and manufactures patient-centric respiratory devices designed for scale and affordability, focusing on improving access to care in India and other global markets. The company is supported by Venture Center, the Department of Science and Technology Government of India, AIC-CCMB, and the Startup India Seed Fund.